Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 15/20 | 0.63 |
| ▸ | MTOR | P42345 | 4/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.40 |
| ▸ | TUBB | P07437 | 4/20 | 0.40 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.40 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.40 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.40 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.40 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.40 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.40 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.40 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.40 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.40 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.40 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL165929 | 0.84 | PIK3CA (0.64) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL166866 | 0.83 | PIK3CA (0.66) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL168153 | 0.83 | PIK3CA (0.66) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL167134 | 0.82 | PIK3CA (0.45) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL164532 | 0.81 | PIK3CA (0.63) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL166994 | 0.81 | PIK3CA (0.61) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL115800 | 0.80 | PIK3CA (0.65) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL168050 | 0.80 | PIK3CA (0.62) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL166232 | 0.80 | PIK3CA (0.60) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL113938 | 0.80 | PIK3CA (0.60) | PIK3CAMTORPIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424859-B1 | INHIBITORS OF PI3 KINASE AND / OR MTOR | AMGEN INC (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8772480-B2 | Inhibitors of PI3 kinase and/or mTOR | AMGEN INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130079303-A1 | Inhibitors of PI3 Kinase and/or mTOR | AMGEN INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-8362241-B2 | Inhibitors of PI3 kinase and/or mTOR | AMGEN INC. (US) | 2013-01-29 | — | — | US | disclosed |
| EP-2424859-A1 | INHIBITORS OF PI3 KINASE AND / OR MTOR | Amgen, Inc (US) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010126895-A1 | INHIBITORS OF PI3 KINASE AND / OR MTOR | AMGEN INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20100273764-A1 | INHIBITORS OF PI3 KINASE AND/OR MTOR | AMGEN INC. (US) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273764-A1 | INHIBITORS OF PI3 KINASE AND/OR MTOR | MTOR, PIK3CA, PIK3CD | PIK3CA 2/4885MTOR 1/4885PIK3CD 3/4885 |
| US-20130079303-A1 | Inhibitors of PI3 Kinase and/or mTOR | MTOR, PIK3CA, PIK3CD | PIK3CA 2/4885MTOR 1/4885PIK3CD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.